Nature Communications (May 2022)

Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

  • Juanjie Tang,
  • Tanya Novak,
  • Julian Hecker,
  • Gabrielle Grubbs,
  • Fatema Tuz Zahra,
  • Lorenza Bellusci,
  • Sara Pourhashemi,
  • Janet Chou,
  • Kristin Moffitt,
  • Natasha B. Halasa,
  • Stephanie P. Schwartz,
  • Tracie C. Walker,
  • Keiko M. Tarquinio,
  • Matt S. Zinter,
  • Mary A. Staat,
  • Shira J. Gertz,
  • Natalie Z. Cvijanovich,
  • Jennifer E. Schuster,
  • Laura L. Loftis,
  • Bria M. Coates,
  • Elizabeth H. Mack,
  • Katherine Irby,
  • Julie C. Fitzgerald,
  • Courtney M. Rowan,
  • Michele Kong,
  • Heidi R. Flori,
  • Aline B. Maddux,
  • Steven L. Shein,
  • Hillary Crandall,
  • Janet R. Hume,
  • Charlotte V. Hobbs,
  • Adriana H. Tremoulet,
  • Chisato Shimizu,
  • Jane C. Burns,
  • Sabrina R. Chen,
  • Hye Kyung Moon,
  • Christoph Lange,
  • Adrienne G. Randolph,
  • Surender Khurana

DOI
https://doi.org/10.1038/s41467-022-30649-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

The antibody response to the SARS-CoV-2 Omicron variant is not well studied in children. Here, the authors provide an age-stratified analysis of SARS-CoV-2 neutralizing capacity of sera from children with acute or convalescent COVID-19 as well as children with multisystem inflammatory syndrome.